Domvanalimab and Zimberelimab in Advanced Liver Cancers

Phase 2 Active not recruiting 58 enrolled University of Texas Southwestern Medical Center Arcus Biosciences, Inc. · collab Cancer Prevention Research Institute of Texas · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to learn about advanced liver and bile duct cancers. The main question it aims to answer is: If the combination of Domvanalimab and Zimberelimab are effective in treating advanced hepatobiliary cancers that have failed prior treatment.

Timeline

Start: 2023-06-12
Primary completion: 2027-12-31
Completion: 2029-12-31

Publications

Hsiehchen D, Kainthla R, Kline H, Siglinsky E, Ahn C, Zhu H. Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial. Nat Commun. 2025 Jul 1;16(1):5819. doi: 10.1038/s41467-025-60757-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Domvanalimab	Monoclonal antibody	1200 mg	Intravenous
Subject	Zimberelimab	Monoclonal antibody	360 mg	Intravenous

Domvanalimab and Zimberelimab in Advanced Liver Cancers

Summary

Timeline

Publications

Drugs

Indications